Aurum Healthcare, a sterilisation services provider for medical devices and instruments, has been acquired by Accuron Technologies, which purchased a majority stake in the company to fully-integrate its suite of medical device outsourcing services.

Following the transaction, Aurum will become part of Accuron’s Advanced Materials Technologies (AMT). The acquisition will add Aurum’s 20,000ft² facility in Johor Bahru, Malaysia, to AMT’s existing manufacturing footprint of 120,000ft² facilities located in Singapore and China.

Merit Medical Systems has completed its acquisition of DFINE, an American medical device company specialising in minimally-invasive therapeutic devices, for a cash consideration of $97.5m.

"The related sales divisions will be restructured to focus more on its broad portfolio of products."

Following the acquisition, Merit’s oncology segments including embolics, microcatheters and biopsy products will be combined into a newly-created interventional oncology and spine division (IOS). The related sales divisions will be restructured to focus more on its broad portfolio of products.

Shanghai Runda Medical Technology intends to acquire 45% stake in Hangzhou Yi Dan Biotechnology from Hangzhou Yee Wo Investment Management Partnership, for CNY216m ($32.45m).

All the three companies involved in the transaction are based in China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.